Key result
Specific genetic variants, including PRCP rs2229437 (OR 6.02) and NPPA rs5063 (OR 13.04), were nominally associated with poor response to gliclazide and glimepiride in Filipinos with type 2 diabetes.
Why the study?
Sulfonylureas are commonly used for type 2 diabetes mellitus in the Philippines, but genetic variants associated with poor response to gliclazide and glimepiride in Filipinos needed evaluation.
Do specific genetic variants predict poor responsiveness to gliclazide or glimepiride in Filipino adults with Type 2 Diabetes Mellitus?
Case-Control (n=252)
Yes
Do specific genetic variants predict poor responsiveness to gliclazide or glimepiride in Filipino adults with Type 2 Diabetes Mellitus?
Odds Ratio: 6.02 (95% CI 1.75–26.73)
p-value: p=0.002
Specific genetic variants, including those in carboxypeptidase-associated genes and the CLCN6-NPPA-MTHFR cluster, show nominal associations with poor response to sulfonylureas in Filipino patients with Type 2 Diabetes.
Should not yet change sulfonylurea prescribing in Filipinos; hypothesis-generating and requires validation.
Introduction: Sulfonylureas (SUs) are commonly used drugs for type 2 diabetes mellitus (T2DM) in the Philippines. This study aimed to associate genetic variants with poor response to gliclazide and glimepiride among Filipinos. Methodology: Two independent, dichotomous longitudinal substudies enrolled 139 and 113 participants in the gliclazide and glimepiride substudies, respectively. DNA from blood samples underwent customized genotyping for candidate genes using microarray. Allelic and genotypic features and clinical associations were determined using exact statistical methods. Results: loci. Conclusion: Genetic variants were found to have a nominal association with sulfonylurea response among Filipinos. These findings can guide for future study directions on pharmacotherapeutic applications for sulfonylurea treatment in this population.
No takes yet. Share an insight, caveat, or question.
Paz-Pacheco et al. (2022) conducted a case-control in Type 2 Diabetes Mellitus (n=252). Genetic variants (e.g., PRCP rs2229437) vs. Wild-type/non-risk genotypes was evaluated on Poor response to sulfonylurea monotherapy (HbA1c change <0.5% from baseline after 3 months) (OR 6.02, 95% CI 1.75-26.73, p=0.002). Specific genetic variants, including PRCP rs2229437 (OR 6.02) and NPPA rs5063 (OR 13.04), were nominally associated with poor response to gliclazide and glimepiride in Filipinos with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: